Cd4+ Cd25+ T-cells activated to a specific antigen
AssigneeNew South Innovations Pty Limited
InventorsBruce M. Hall, Suzanne J. Hodgkinson
Life of this patent
Estimating the term…
Loading patent…
AssigneeNew South Innovations Pty Limited
InventorsBruce M. Hall, Suzanne J. Hodgkinson
Estimating the term…
The invention relates to a method of assessing whether a subject comprises CD4+,CD25+ T cells that have been activated to a specific antigen. The method comprises the steps of obtaining from the subject a sample of lymphocytes comprising CD4+,CD25+ T cells, incubating at least one portion of the sample of lymphocytes so as to promote distinction of CD4+,CD25+ T cells that have been activated to the specific antigen from those CD4+,CD25+ T cells that have not been activated to the specific antigen, and thereafter determining whether CD4+,CD25+ T cells activated to the specific antigen are present in the sample. The invention further relates to methods of growing CD4+, CD25+ T cells that have been activated to a specific antigen in vitro and to methods of increasing tolerance in a subject using the CD4+, CD25+ T cells that have been grown in vitro.
A method of assessing whether a subject comprises CD4+, CD25+high T cells that have been activated to a specific non-self antigen, and is therefore tolerant, or capable of becoming tolerant, to the specific non-self antigen, the method of comprising:
Dependencies are inferred from the claim text.